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ABSTRACT
A rapid and sensitive microbore high-performance liquid chromatography (HPLC) coupled to microdialysis technique for simultaneous determination of unbound hesperetin in rat blood and brain has been developed. The HPLC assay was carried out using a microbore
reversed-phase C-18 column (100 × 1 mm I.D., 5 µm particle size). The mobile phase used was acetonitrile-methanol-20 mM monosodium phosphate (pH 5.3) (40:10:50, v/v/v) for hesperetin at a flow-rate of 0.05 mL/min. The assay was performed by monitoring the wavelength of maximum UV absorbance at 288 nm. Microdialysis probes were inserted into the jugular vein/right atrium and brain striatum of
male Sprague-Dawley rats. Hesperetin (50 mg/kg, i.v., n=6) was administered via the femoral vein, and microdialysates were collected
from both sites and assayed by the validated microbore scale HPLC method. Pharmacokinetic parameters were calculated from the corrected data for dialysate concentrations of hesperetin versus time.
Key words: hesperetin, microdialysis, pharmacokinetics, microbore HPLC

INTRODUCTION
Hesperetin (Figure 1) is an aglycon without rutinose
sugar moiety of hesperidin. Hesperetin and hesperidin are the
major flavones in the peels of Citrus reticulata and its variants (1,2) which has first isolated in the early 1930s(3-6).
Recently hesperetin was also isolated from the leaves of
Buddleja madagascariensis Lamk, which is widely distributed in Egypt(7). Hesperetin inhibited both epinephrine- and
theophylline-induced lipolysis in rat adipocytes(8) and was
active against human intestinal microflora Helicobacter
pylori with MIC 20-80 µg/mL(9). Numerous techniques have
been used to determine hesperetin or its related compounds,
for example, HPLC-UV(2,10), GC-MS(11), HPLC-MS(12) and
capillary electrophoresis(13,14). Although, numerous studies
describing the plasma pharmacokinetics of hesperetin or its
related compounds(15,16) have been reported, the pharmacokinetics of unbound hesperetin in blood and brain are not
available. Microdialysis is a technique that enables the measurement of protein-unbound drug concentrations as a function of time and is therefore suitable for pharmacokinetic

Figure 1. Chemical structure of hesperetin.
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studies. The total drug concentration in the biological fluid
does not immediately reflect concentrations at the cellular
level for the pharmacological response. Therefore, monitoring the drug concentration in the interstitial space is crucial
for understanding the time course of biological activity of the
drug(17).
Of the several techniques that have been employed to
study the transportation of the drug to the brain, the conventional way was to assay the drug concentration in the brain
tissue homogenate. Microdialysis, on the other hand, is an in
vivo sampling technique that offers several advantages. It
mainly provides an opportunity to monitor drug concentration continuously and simultaneously while coupled to a suitable analytical technique(18,19). Microdialysis procedures
have been used for the measurement of protein-free drugs,
because protein molecules are too large to pass through the
dialysis membrane (molecular weight cut-off 13 kD). These
procedures therefore allow determination of unbound drug
concentrations in extracellular space in most tissues(20,21).
Due to the limitation of the analytical technique, finite volumes of dialysates collected at a slower perfusing rate are
required. The measured drug concentrations therefore actually represent the average drug concentrations for a given time
period.
In this study, we have constructed blood and brain
microdialysis probes, then inserted them into the rat jugular
veins and brain striata for sampling of biological fluids after
hesperetin was administered intravenously. The quantitative
analysis was carried out using validated microbore HPLC
systems. The microdialysis technique therefore, appears to be
a suitable approach for unbound drug monitoring at a specif-
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ic site in pharmacokinetic studies.

MATERIALS AND METHODS
I. Reagents
Hesperetin (Figure 1) and chemical reagents were purchased from Sigma (St. Louis, MO, USA). The chromatographic solvents were obtained from BDH (Poole, UK).
Triple de-ionized water from Millipore (Bedford, MA, USA)
was used for all preparations. The standard solution of hesperetin was accurately weighted and dissolved in methanol to
give serial concentrations in the range 0.001-1 µg/mL. A calibration graph was plotted by linear regression of the peakarea ratios with concentration.
II. Liquid Chromatography
The liquid chromatographic system consisted of a chromatographic pump (Bioanalytical System, BAS PM-80, West
Lafayette, IN, USA), an on-line injector (CMA 160,
Stockholm, Sweden) equipped with a 10 µL sample loop and
a Dynamax UV/Vis detector (Walnut Creek, CA, USA).
Dialysates were separated using a reversed phase C18 microbore column (150 × 1 mm I.D.; particle size 5 µ m,
Bioanalytical System) maintained at an ambient temperature
to perform the ideal chromatographic phase. The mobile
phase consisted of acetonitrile-methanol-20 mM monosodium phosphate (pH 5.3) (40:10:50, v/v/v) with a flow rate of
0.05 mL/min. The mobile phase mixture was filtered through
a 0.22 µm Millipore membrane, then degassed prior to use.
The detection wavelength for hesperetin was set at 288 nm.
Output data from the detector were integrated via an
EZChrom chromatographic data system (Scientific Software,
San Ramon, CA, USA).
III. Animals
All experimental protocols involving animals were
reviewed and approved by an institutional animal experimentation committee of the National Research Institute of
Chinese Medicine. Male specific pathogen-free rats of the
Sprague-Dawley strain were obtained from the Laboratory
Animal Science Center of the National Yang-Ming
University, Taipei. The animals had free access to food
(Laboratory rodent diet #5P14, PMI Feeds Inc., Richmond,
IN, USA) and water until 18 hr prior to experiments, after
which food was removed. The rats were initially anesthetized
with sodium pentobarbital (50 mg/kg, i.p.), and remained
anesthetized throughout the experimental period and body
temperatures maintained at 37˚C with a heating blanket.
These animals were specifically pathogen-free and were
allowed to acclimatize in their environmentally controlled
quarters (24 ± 1˚C and 12:12 hr light-dark cycle) for at least
5 days before experimentation.
IV. Blood and Brain Microdialysis

The blood microdialysis system consisted of a
CMA/100 microinjection pump, a CMA-160 on-line microdialysis injector for the blood sampling and a CMA-140
microfraction collector for brain dialysate collection.
Dialysis probes, concentric in design, were made of silica
glass with a 10 mm (for blood) and 4 mm (for brain) dialyzing surface (Spectrum, 150 µm diameter, nominal molecular
weight cut-off 13000 Da)(22). Flexible and rigid microdialysis probes were applied to sample the unbound endogenous
or exogenous substances in rat blood (Figure 2) and brain
(Figure 3), respectively. The microdialysis probes were
inserted into the right jugular veins of the rat, and then perfused with anticoagulant ACD solution (pH 4.5; citric acid
3.5 mM; sodium citrate 7.5 mM; dextrose 13.6 mM) at a
flow-rate of 1 µ L/min, using a microinjection pump
(CMA/100). Following jugular vein surgery, the rat was
mounted on a Kopf stereotaxic frame for brain microdialysis.
The brain microdialysis probe was perfused with Ringer’s
solution (147 mM Na+; 2.2 mM Ca++; 4 mM K+; pH 7.0) at a
flow-rate of 1 µL/min. After washing with Ringers solution,
external
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Figure 2. The microdialysis probe used for sampling rat blood. (A) A
microdialysis probe inserted into the rat jugular vein/right atrium, (B)
the compositions of hand-made microdialysis probe.

Brain Microdialysis

A. System controller
B. Microinjection pump
C. Syringe selector
D. Stereotaxic frame

E. microfraction collector
F. Microinjection pump
G. Temperature controller

Figure 3. The brain microdialysis for rats. A: System Controller. B:
Microinjection Pump I. C: Syringe Selector. D: Stereotaxic Frame. E:
Microfraction Collector. F: Microinjection Pump II. G: Temperature
Controller.
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the microdialysis probe was implanted in the right striatum
(coordinates: AP 0.2 mm; ML –3.0 mm; DV –7.0 mm)
according to Paxinos and Watson atlas(23). When dialysate
levels had been stabilized (approximately 2 hr), hesperetin
(50 mg/kg) was intravenously administered via femoral vein.
The positions of the probes were verified by a standard histological procedure at the end of the experiments.

Clast/λZ; AUMC = AUMClast + (tlast • Clast/λZ) + Clast/(λZ)2; here
Clast and tlast are the last observed concentration and time,
respectively; λZ is the terminal slope which is estimated by
linear regression of the logarithmic value of the last observed
data. The clearance (Cl) and the mean residence time (MRT)
were estimated as follows: Cl = Dose / AUC and MRT =
AUMC / AUC. The volume of distribution at steady state
(Vd) was estimated by means of Vd = Cl • MRT(26).

V. Recovery of Hesperetin from Microdialysis Probe
For in vitro recovery, the blood and brain microdialysis
probes were immersed in Ringer's solution containing hesperetin (1 or 2 µg/mL) which was passed through the microdialysis probe at a constant flow rate (1 µL/min) using an
infusion pump (CMA/100). The inlet (Cin) and outlet (Cout)
concentrations of hesperetin were determined by HPLC. The
in vitro recovery ratio (Recovery in vitro) of hesperetin across a
microdialysis probe was calculated by the following equation(24): Recovery in vitro = [(Cout)/Cin] × 100%.

RESULTS AND DISCUSSION

Protein unbound hesperetin concentration data were
obtained by correcting the microdialytic data for in vitro
recovery of the respective microdialysis probes. Pharmacokinetic calculations were obtained by the WinNonlin software program (version 1.1, Scientific Consulting Inc., Apex,
NC, USA) following non-compartmental model (25). The
incremental areas under the concentration curves (AUC) and
area under the moment versus time curve (AUMC) were calculated using the linear trapezoid method. AUC = AUClast +

Hesperetin in both blood and brain dialysates was adequately resolved using the validated microbore HPLC conditions. Isocratic separation of hesperetin from certain endogenous chemicals in the blood or brain dialysate was achieved
in an optimal mobile phase containing 50% of 20 mM
monosodium phosphate (pH 5.3), 40% of acetonitrile and
10% of methanol. The retention time of hesperetin was 5.6
min (Figure 4). Figure 4A shows a standard chromatogram of
hesperetin (0.5 µg/mL). Figure 4B shows a chromatogram of
a blank blood dialysate. None of the observed peaks interfered with the analyzed compounds. Figure 4C shows the
chromatogram of a blood dialysate sample containing hesperetin (0.45 µg/mL) collected at 20 min after hesperetin
administration (50 mg/kg, i.v.). In contrast to other existing
methods(2,10), the automatic hyphenation of microdialysis
coupled with microbore HPLC saves time compared to complicated sample extraction procedures and also minimizes
solvent consumption.
Figure 5A shows a typical chromatogram of standard
hesperetin (0.02 µg/mL). Figure 5B shows a chromatogram

Figure 4. Typical chromatograms of (A) standard hesperetin (0.5
µg/mL), (B) a blank blood dialysate, and (C) a blood dialysate sample
containing hesperetin (0.45 µg/mL) collected from jugular vein at 20
min after hesperetin administration (50 mg/kg, i.v.). Peak 1: hesperetin.

Figure 5. Typical chromatogram for injection of (A) standard hesperetin (0.02 µg/mL), (B) a blank brain dialysate, and (C) a braindialysate sample containing hesperetin (0.015 µg/mL) collected from
brain striatum at 30 min after hesperetin administration (50 mg/kg, i.v.).
Peak 1: hesperetin.

VI. Pharmacokinetics
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of a blank brain dialysate. None of the observed peaks interfered with either analyzed compounds. Figure 5C shows the
chromatogram of a brain dialysate sample containing hesperetin (0.015 µg/mL) collected at 30 min after the administration (50 mg/kg, i.v.).
The intraday-assay and interday-assay precision and
accuracy of hesperetin fell well within the predefined limits
of acceptability. All values of percent bias and percent of relative standard deviations (R.S.Ds) were within ± 15% (Table
1). The limit of detection was approximately 1 ng/mL for
hesperetin. The average in vitro microdialytic recoveries of
hesperetin (1.000 and 2.000 µg/mL) in blood and brain were
25.7 ± 1.7% and 10.4 ± 1.8%, respectively (Table 2). This
method is sufficiently sensitive for measurement of unbound
hesperetin in rat blood and brain in a pharmacokinetic study.
However, care must be taken to prevent obstruction of the
microbore column during the experiment.
The pharmacokinetic parameters of hesperetin in the
blood and brain are given in Table 3. The average ratio of the
area under the concentration curves of hesperetin in brain to
blood (AUCbrain/AUCblood) is 12% for 50 mg/kg hesperetin
administration. The average unbound brain/blood concentration ratio of hesperetin increased and reached the highest
ratio at 20 min after intravenous administration of hesperetin
(Figure 6). The ratio of the area under the concentration
curves of hesperetin in brain to blood (AUCbrain / AUCblood)
was used as a measurement of the drug penetration through
Table 1. Intraday-assay and interday-assay accuracy and precision of
the HPLC method for determination of hesperetin
Nominal
Observed
Concentration
Concentration
R.S.D.
Accuracy
(µg/mL)
(µg/mL)a
(%)
(% Bias)
Intraday-assay (n=6)
11.1
–10.0
0.010
0.009 ± 0.001
5.6
–10.0
0.020
0.018 ± 0.001
3.7
8.0
0.050
0.054 ± 0.002
2.1
–6.0
0.100
0.094 ± 0.002
1.5
0.5
0.200
0.201 ± 0.003
0.8
1.8
0.500
0.509 ± 0.004
1.000
0.995 ± 0.003
0.3
-0.5
Interday-assay (n=6)
9.1
10.0
0.010
0.011 ± 0.001
5.3
–5.0
0.020
0.019 ± 0.001
7.8
2.0
0.050
0.051 ± 0.004
3.2
–7.0
0.100
0.093 ± 0.003
5.9
1.0
0.200
0.202 ± 0.012
4.5
2.6
0.500
0.513 ± 0.023
1.000
0.962 ± 0.025
2.6
–3.8
a Observed concentration data are expressed as mean ± S.D.
Table 2. In vitro microdialysate recoveries (%) of hesperetin in rat
blood and brain
Concentration (µg/mL)
Recovery (%)
In rat blood
1.000
24.6 ± 1.5
2.000
26.8 ± 1.1
In rat brain
1.000
11.1 ± 2.2
2.000
9.7 ± 0.8
Data are expressed as mean ± S.D. (n=6).

blood-brain barrier(17). This steadily increasing ratio suggests
that hesperetin penetrated through the blood-brain barrier(27,28).
The present microdialysis technique provides proteinfree samples that can be directly injected into a liquid chromatographic system for continuous in vivo monitoring of
unbound drugs in biological samples such as blood or brain.
Furthermore, this sampling method facilitates pharmacokinetic studies by reducing the effects of biological volume
changes as compared to conventional biological fluid withdrawing assays(17-19). In view of the labile nature of hesperetin, an on-line microdialysis technique was used in this
study. Its potential for studying the pharmacokinetics of hesperetin in rat blood and brain was convincingly demonstrated
in this study. Several in vivo techniques have been described
for brain pharmacokinetic studies, including autoradiography, imaging methods (PET-positron emission tomography
and NMR-nuclear magnetic resonance), cerebral fluid sampling, in vivo voltammetry, and intracerebral microdialysis.
However, these techniques are too expensive for general laboratory use. Although intracerebral microdialysis has the disadvantage of being invasive, it is much cheaper than PET
scanning or NMR and can be used in the general laboratory(17,29).
Table 3. Pharmacokinetic parameters of hesperetin in rat blood and
brain following hesperetin administration (50 mg/kg, i.v., n=6)
Parameters
Estimate
Blood
28.88 ± 4.10
t1/2,z (min)
191.54 ± 46.97
AUC (min µg/mL)
Cl (L/kg/min)
0.35 ± 0.02
MRT (min)
9.66 ± 1.78
3.34 ± 0.78
Vdss (L/kg)
Brain
19.80 ± 6.28
t1/2,z (min)
23.07 ± 18.23
AUC (min µg/mL)
MRT (min)
38.17 ± 3.36
Data are expressed as mean ± S.E.M. (n=6).

Figure 6. Mean levels of unbound hesperetin in rat blood and brain
after hesperetin administration (50 mg/kg, i.v., n=6).
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In summary, we have presented in this paper a study of
the pharmacokinetics of unbound hesperetin in blood and
brain after intravenous administration to rats. This method
exhibits no endogenous interference and is sufficient sensitive for blood and brain dialysates.
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摘

要

本實驗應用一套快速、靈敏的微管高效液相層析技術，偵測大白鼠腦部和血液中的非結合態橙皮素，此
技術已發展應用於藥品的採樣。高效液相層析系統中，使用逆相碳 18 微管柱 (100 × 1 mm I.D., 粒徑 5 µm)，
移動相為 acetonitrile-methanol-20 mM monosodium phosphate (pH 5.3) (40:10:50, v/v/v)，流速 0.05 mL/min ，紫
外光偵測波長設定在最大吸收值 288 nm 。微透析探針分別插入雄性大白鼠的頸靜脈（即進入右心房）和腦
部紋狀體。實驗方法是將橙皮素注入六隻大白鼠的股靜脈，每隻大白鼠之注射劑量為 50 mg/kg ，然後分別收
集血液與腦部之微透析液並進行分析。根據所得之個體數據可計算藥物動力學參數，並求得橙皮素透析液濃
度與時間之關係。
關鍵詞：橙皮素，微透析，藥物動力學，微管高效液相層析

